MedElevator Войти в исследования
← Поиск публикаций

DOI 10.17219/acem/195187

Медицинская библиотека · Advances in clinical and experimental medicine : official organ Wroclaw Medical University · 2025

RNA binding protein ELAVL1 is associated with severity and prognosis of hepatocellular carcinoma patients: A retrospective study.

Ji Guibao, Guo Qiuxia, Chen Langning, Chen Jingyu, Li Zhuolin

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, which is characterized by a lack of sensitive and specific biomarkers.

OBJECTIVES

This study investigates the association between ELAV-like RNA binding protein 1 (ELAVL1) and HCC patient outcomes.

MATERIAL AND

METHODS

This retrospective study encompassed 108 HCC patients who reported to Wuhan Fourth Hospital and Tongji Hospital, China, from January 2016 to August 2020. Clinical data collected included age, sex, body mass index (BMI), comorbidities, tumor-node-metastasis (TNM) stage, Barcelona Clinic Liver Cancer (BCLC) stage, and lymphatic metastasis. All patients received routine follow-up for survival and recurrence status ranged from 36 to 60 months. The serum levels of ELAVL1 were tested using enzyme-linked immuno-sorbent assay (ELISA). Levels of total bilirubin, alanine aminotransferase (ALT), aspartate transaminase (AST), HCC-related biomarkers of alpha fetoprotein (AFP), α-L-fucosidase (AFU), and carcinoembryonic antigen (CEA) were recorded.

RESULTS

Our findings revealed a significantly higher expression of ELAVL1 in patients presenting with TNM stages III-IV, BCLC stages C-D, lymphatic metastasis, as well as deceased and recurrent patients. Receiver operating characteristic (ROC) curves showed that the areas under the curve (AUCs) for ELAVL1 in predicting mortality, recurrence and poor prognosis (defined as mortality or recurrence) in HCC patients were 0.818, 0.732 and 0.827, respectively. Patients with higher expression of ELAVL1 showed significantly higher frequencies of TNM III-IV stages, BCLC D stage, lymphatic metastasis, higher mortality, and recurrence ratio, as well as higher AFP and CEA levels. ELAVL1 was positively correlated with levels of AFP and CEA. Higher BCLC stage, lymphatic metastasis, age, AFP, and ELAVL1 were independent risk factors for poor prognosis of HCC patients.

CONCLUSIONS

Higher serum levels of ELAVL1 are associated with worse clinical outcomes and poorer prognosis in ‑HCC patients.

Для цитирования: Ji Guibao, Guo Qiuxia, Chen Langning, Chen Jingyu, Li Zhuolin. RNA binding protein ELAVL1 is associated with severity and prognosis of hepatocellular carcinoma patients: A retrospective study.. Advances in clinical and experimental medicine : official organ Wroclaw Medical University. 2025. DOI: 10.17219/acem/195187.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.